

MIGRAINE PREVENTION AGENTS PRIOR AUTHORIZATION FORM (form effective 1/6/2025)

Prior authorization guidelines for **Migraine Prevention Agents** and **Quantity Limits/Daily Dose Limits** are available on the DHS Pharmacy Services website at <https://www.pa.gov/en/agencies/dhs/resources/for-providers/ma-for-providers/pharmacy-services.html>.

<input type="checkbox"/> New request	<input type="checkbox"/> Renewal request	# of pages: _____	Prescriber name:	
Name of office contact:			Specialty:	
Contact's phone number:			NPI:	State license #:
LTC facility contact/phone:			Street address:	
Beneficiary name:			City/State/Zip:	
Beneficiary ID#:	DOB:	Phone:	Fax:	

CLINICAL INFORMATION

Drug requested:	Strength:	Formulation (pen, syringe, tablet, etc):	
Dose/directions:		Quantity:	Refills:
Diagnosis (<i>submit documentation</i>):		Dx code (<i>required</i>):	
Is the drug prescribed by or in consultation with a headache specialist who is certified in headache medicine by the United Council for Neurologic Subspecialties or a neurologist?		<input type="checkbox"/> Yes <i>Submit documentation of</i> <input type="checkbox"/> No <i>consultation, if applicable.</i>	

Complete all sections that apply to the beneficiary and this request.

Check all that apply and submit documentation for each item.

INITIAL requests

1. For PREVENTION OF MIGRAINE:

- Averaged 4 or more migraine days per month over the past 3 months
- Tried and failed (or cannot try) at least 1 other preventive migraine drug from 1 of the following 3 classes:
 - Anticonvulsants (e.g., divalproex, topiramate, valproic acid)
 - Antidepressants (e.g., amitriptyline, venlafaxine)
 - Beta blockers (e.g., metoprolol, propranolol, timolol)

2. For EPISODIC CLUSTER HEADACHE:

- Tried and failed (or cannot try) at least one other preventive medication

3. For a GEPANT (e.g., Nurtec ODT, Qulipta) for PREVENTION OF MIGRAINE:

- Tried and failed (or cannot try) at least 2 preferred CGRP monoclonal antibodies approved or medically accepted for the diagnosis (*Refer to <https://papdl.com/preferred-drug-list> for a list of preferred and non-preferred Migraine Prevention Agents.*)
- For a NON-PREFERRED gepant for prevention of migraine:
 - Tried and failed (or cannot try) the preferred gepants approved or medically accepted for the indication (*Refer to*

<https://papdl.com/preferred-drug-list> for a list of preferred and non-preferred gepants.)

4. For all other NON-PREFERRED Migraine Prevention Agents (except gepants):

- Tried and failed or has a contraindication or intolerance to the preferred Migraine Prevention Agents approved or medically accepted for the diagnosis (Refer to <https://papdl.com/preferred-drug-list> for a list of preferred and non-preferred Migraine Prevention Agents.)

RENEWAL requests

1. For PREVENTION OF MIGRAINE:

- Experienced fewer average migraine days or headache days per month since starting the requested medication
 Experienced a decrease in severity or duration of migraines since starting the requested medication

2. For EPISODIC CLUSTER HEADACHE:

- Experienced a reduction in the frequency of episodic cluster headache since starting the requested medication

3. For a GEPANT (e.g., Nurtec ODT, Qulipta) for PREVENTION OF MIGRAINE:

- Tried and failed (or cannot try) at least 2 preferred CGRP monoclonal antibodies approved or medically accepted for the indication (Refer to <https://papdl.com/preferred-drug-list> for a list of preferred and non-preferred Migraine Prevention Agents.)

For a NON-PREFERRED gepant for prevention of migraine:

- Tried and failed (or cannot try) the preferred gepants approved or medically accepted for the diagnosis (Refer to <https://papdl.com/preferred-drug-list> for a list of preferred and non-preferred gepants.)

4. For all other NON-PREFERRED Migraine Prevention Agents (except gepants):

- Tried and failed or has a contraindication or intolerance to the preferred Migraine Prevention Agents approved or medically accepted for the diagnosis (Refer to <https://papdl.com/preferred-drug-list> for a list of preferred and non-preferred Migraine Prevention Agents.)

PLEASE FAX COMPLETED FORM WITH REQUIRED CLINICAL DOCUMENTATION TO 866-240-3712

Prescriber Signature:

Date:

Confidentiality Notice: The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.